within Pharmacolibrary.Drugs.ATC.M;

model M04AB05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.00011,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.04,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.038,
    k12             = 10.9,
    k21             = 10.9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M04AB05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lesinurad is a selective uric acid reabsorption inhibitor (SURI) used in combination with xanthine oxidase inhibitors to treat hyperuricemia associated with gout. It acts by inhibiting the uric acid transporter URAT1 in the kidneys, thereby increasing uric acid excretion. It was approved for use but has since been withdrawn from the market in several countries due to business reasons rather than safety concerns.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from studies in healthy adult subjects, single oral dose of 200 mg under fasting conditions.</p><h4>References</h4><ol><li><p>Shen, Z, et al., &amp; Storgard, C (2015). Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. <i>Drug design, development and therapy</i> 9 3423–3434. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S85193&quot;>10.2147/DDDT.S85193</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26170627/&quot;>https://pubmed.ncbi.nlm.nih.gov/26170627</a></p></li><li><p>Gillen, M, et al., &amp; Shen, Z (2016). Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers. <i>Drug design, development and therapy</i> 10 3555–3562. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S119944&quot;>10.2147/DDDT.S119944</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27843295/&quot;>https://pubmed.ncbi.nlm.nih.gov/27843295</a></p></li><li><p>Shen, Z, et al., &amp; Gillen, M (2019). Effects of Food and Antacids on Pharmacokinetics and Pharmacodynamics of Lesinurad, a Selective Urate Reabsorption Inhibitor. <i>Clinical pharmacology in drug development</i> 8(5) 647–656. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.663&quot;>10.1002/cpdd.663</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30748125/&quot;>https://pubmed.ncbi.nlm.nih.gov/30748125</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M04AB05;
